Furthermore, DTR+ pancreatic tumours, whether treated with anti-PDL1 or isotype control, showed a near complete ablation of LRRC15+ CAFs and a significant reduction in the total PDPN+ fibroblast compartment (Extended Data Fig. 7c-e). This evidence concerns the gene PDPN and pancreatic neoplasm.